-
Mashup Score: 0C. difficile infection recurrence after FMT higher than previously reported in IBD - 12 month(s) ago
CHICAGO — More than 20% of patients with inflammatory bowel disease experienced recurrent Clostridioides difficile infection 1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week. “While there are data on the short-term efficacy of FMT for eradicating C. diff infections in patients with IBD, there is less known about longer-term
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 0Physical Fitness and Inflammatory Bowel Disease Risk Among Children and Adolescents in Taiwan - 1 year(s) ago
This cohort study examines the association between physical fitness and subsequent risk for inflammatory bowel disease among children and adolescents in Taiwan.
Source: jamanetwork.comCategories: Latest Headlines, PediatricsTweet-
Study findings suggest that better cardiorespiratory endurance among youths is associated with lower subsequent risk for #InflammatoryBowelDisease. https://t.co/BrK9f9SP7t
-
-
Mashup Score: 0
Expert gastroenterologists delve into the long-term management of Crohn’s disease and ulcerative colitis and examine the latest treatment options and strategies to enhance patient outcomes.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
In this video, expert gastroenterologists delve into the long-term management of Crohn’s disease and #UlcerativeColitis and examine the latest treatment options and strategies to enhance patient outcomes. https://t.co/erTIBA9M3v #InflammatoryBowelDisease
-
-
Mashup Score: 5
Cedars-Sinai investigators have identified a genetic variant that increases people’s risk of developing perianal Crohn’s disease, the most debilitating manifestation of Crohn’s disease.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Study gives insight into cause of severe #inflammatoryboweldisease https://t.co/bPFsN3zvSB
-
-
Mashup Score: 0
In this podcast Mairi McLean talks to Professor Jon Rhodes about his recently published paper “Recent advances in clinical practice: a systematic review of isolated colonic Crohn’s disease: the third
Source: SoundCloudCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
‘A systematic review of isolated colonic Crohn's disease: the third IBD?’ 👇 In this podcast Mairi McLean talks to Professor Jon Rhodes about his recently published paper. Listen now: 🎧 https://t.co/6KyJJgmguD #IBD #InflammatoryBowelDisease https://t.co/6KGbAzpN1T
-
-
Mashup Score: 0AGA launches ‘My IBD Life’ campaign to provide resources, support for patients, physicians - 1 year(s) ago
With recent data highlighting the emotional and social challenges of inflammatory bowel disease, AGA has launched the “My IBD Life” campaign to address the growing need for psychosocial support in patient care. According to an AGA press release, a survey of 1,026 patients with IBD aged 18 to 59 years found that nearly two-thirds reported comorbid conditions, with more than one in
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
With recent data highlighting the #emotional and #social challenges of #inflammatoryboweldisease, @AmerGastroAssn has launched the “My #IBD Life” campaign to address the growing need for #psychosocial support in #patient care. @drlauriekeefer #GITwitter https://t.co/LbMtYqB0oV
-
-
Mashup Score: 0
In this podcast Mairi McLean talks to Professor Jon Rhodes about his recently published paper “Recent advances in clinical practice: a systematic review of isolated colonic Crohn’s disease: the third
Source: SoundCloudCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
‘A systematic review of isolated colonic Crohn's disease: the third IBD?’ 👇 In this podcast Mairi McLean talks to Professor Jon Rhodes about his recently published paper. Listen now: 🎧 https://t.co/6KyJJgmOkb #IBD #InflammatoryBowelDisease https://t.co/ns5QCZ2FoT
-
-
Mashup Score: 0FMT Demonstrates Safety, Efficacy for Treatment of Recurrent CDI in Patients With IBD - 1 year(s) ago
Risk of flare in patients with inflammatory bowel disease (IBD) was low after fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridioides difficile infection (CDI).
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Risk of flare in patients with #InflammatoryBowelDisease (IBD) was low after fecal microbiota transplantation (FMT) for the treatment of recurrent #ClostridioidesDifficileInfection (CDI) in this study. Read more! https://t.co/BBkYI7xOh8 https://t.co/QKrJIaQCy8
-
-
Mashup Score: 1FDA 2022 Rewind: GI drug pipeline rattles as FDA delivers 7 new drugs, 1 costly rejection - 1 year(s) ago
Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel disease and several first-in-class therapies, yet the FDA’s rejection of the first hepatitis D therapy still looms large.Over the past year, the FDA has greenlit several notable additions to the gastroenterology armamentarium, including the first treatment for eosinophilic
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#Gastroenterology had a big year in 2022, with potentially game-changing @US_FDA approvals for #inflammatoryboweldisease and several first-in-class therapies, yet the #FDA’s rejection of the first #hepatitisD therapy still looms large #GITwitter https://t.co/8ezMu1Stsc
-
-
Mashup Score: 0FDA agrees on Abivax’s pediatric study plan to develop obefazimod for children with IBD - 1 year(s) ago
The FDA has agreed on Abivax’s initial pediatric study plan for the development of obefazimod in children aged 2 to 17 years with inflammatory bowel disease, the company announced in a press release.In October 2022, Abivax enrolled its first patient in ABTECT, a phase 3 program with obefazimod in adults with moderate to severe ulcerative colitis. With that program underway, Abivax initiated
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
The @US_FDA has agreed on @Abivax_’s initial #pediatric study plan for the development of #obefazimod in children aged 2 to 17 years with #inflammatoryboweldisease, the company announced in a press release. #IBD #GITwitter #MedTwitter https://t.co/naR5GBrysK
-
More than 20% of patients with #inflammatoryboweldisease experienced recurrent #Clostridioidesdifficile infection 1 year after #fecalmicrobiotatransplantation, according to data presented at #DDW23 @EdwardLoftus2 @DDWMeeting https://t.co/zU6DeRH9iC